daratumumab
Genmab receives milestone payment for first Darzalex sale in Europe
May 31, 2016Manufacturing and Production, Sales and Marketing EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales
Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its …
Darzalex meets endpoint in late-stage multiple myeloma trial
May 19, 2016Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial
Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …
Genmab Darzalex success triggers second milestone payment
March 10, 2016Research and Development, Sales and Marketing Genmab, Janssen, daratumumab, darzalex, follicular lymphoma
Genmab says it has reached a $5 million milestone in its daratumumab collaboration with Janssen as a result of success …
Janssen submits EMA application for myeloma drug
September 14, 2015Sales and Marketing Janssen, daratumumab, multiple myeloma
Janssen has submitted a new marketing authorisation application for European approval of daratumumab for the treatment of patients with relapsed …
Priority review for Novartis myeloma drug
November 26, 2014Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac
Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
